AHS 2022 | PROMISE-1 & PROMISE-2: eptinezumab in episodic and chronic migraine

Rami Apelian, MD, MPH, FAES, Huntington Headache and Neurology, Arcadia, CA, discusses the PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) clinical trials, which evaluated the efficacy and safety of eptinezumab in the preventive treatment of episodic and chronic migraine respectively. In both studies, treatment with eptinezumab (100 mg or 300 mg) was associated with significant reductions in monthly migraine days, was well tolerated, and demonstrated an acceptable safety profile. This interview took place during the 2022 American Headache Society (AHS) Meeting in Denver, CO.